As the economy ebbs and flows, pharma and biotech companies alike are feeling the pressure to cut costs. From rapid inflation to the ever-changing regulatory landscape, many are looking for ways to reduce their burn rate.
Posts
inch Therapeutics is slashing its headcount by around 37% and suspending its planned Phase I study in autism one week after Takeda withdrew from its multi-year collaboration, the company announced Thursday.
